CA2689588C - Promoterless cassettes for expression of alphavirus structural proteins - Google Patents
Promoterless cassettes for expression of alphavirus structural proteins Download PDFInfo
- Publication number
- CA2689588C CA2689588C CA2689588A CA2689588A CA2689588C CA 2689588 C CA2689588 C CA 2689588C CA 2689588 A CA2689588 A CA 2689588A CA 2689588 A CA2689588 A CA 2689588A CA 2689588 C CA2689588 C CA 2689588C
- Authority
- CA
- Canada
- Prior art keywords
- alphavirus
- rna
- helper
- rna molecule
- replicon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93663707P | 2007-06-21 | 2007-06-21 | |
| US60/936,637 | 2007-06-21 | ||
| PCT/US2008/007701 WO2008156829A2 (en) | 2007-06-21 | 2008-06-20 | Promoterless cassettes for expression of alphavirus structural proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2689588A1 CA2689588A1 (en) | 2008-12-24 |
| CA2689588C true CA2689588C (en) | 2016-08-23 |
Family
ID=40156867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2689588A Active CA2689588C (en) | 2007-06-21 | 2008-06-20 | Promoterless cassettes for expression of alphavirus structural proteins |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8460913B2 (enExample) |
| EP (2) | EP2947149B1 (enExample) |
| JP (3) | JP5602624B2 (enExample) |
| CN (1) | CN101802199B (enExample) |
| AU (1) | AU2008266807B2 (enExample) |
| CA (1) | CA2689588C (enExample) |
| DK (2) | DK2183368T3 (enExample) |
| ES (2) | ES2670813T3 (enExample) |
| IL (1) | IL202720A (enExample) |
| NZ (1) | NZ582495A (enExample) |
| PL (2) | PL2183368T3 (enExample) |
| WO (1) | WO2008156829A2 (enExample) |
| ZA (1) | ZA200909080B (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2183368T3 (en) * | 2007-06-21 | 2016-09-05 | Alphavax Inc | PROMOTER-FREE CASES FOR EXPRESSION OF ALPHAVIRUS STRUCTURE PROTEINS |
| US8680258B2 (en) | 2008-12-01 | 2014-03-25 | Alphavax, Inc. | Use of microRNAs to control virus helper nucleic acids |
| US20120128714A1 (en) | 2009-04-08 | 2012-05-24 | Wolchok Jedd D | Alphavirus Replicon Particles Expressing TRP2 |
| SI2591114T1 (sl) | 2010-07-06 | 2016-10-28 | Glaxosmithkline Biologicals S.A. | Imunizacija velikih sesalcev z majhnimi odmerki RNA |
| ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
| AU2011276234B2 (en) | 2010-07-06 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Liposomes with lipids having an advantageous pKa- value for RNA delivery |
| WO2012031043A1 (en) | 2010-08-31 | 2012-03-08 | Novartis Ag | Pegylated liposomes for delivery of immunogen-encoding rna |
| EP3520813B1 (en) * | 2010-10-11 | 2023-04-19 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| EP3854413A1 (en) | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| US10494421B2 (en) | 2014-02-10 | 2019-12-03 | Univercells Nv | System, apparatus and method for biomolecules production |
| SI3350333T1 (sl) | 2015-09-17 | 2022-04-29 | ModernaTX,Inc. | Polinukleotidi, ki zajemajo stabilizacijsko repno regijo |
| US10022436B2 (en) | 2016-01-11 | 2018-07-17 | Verndari, Inc. | Microneedle compositions and methods of using same |
| WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
| WO2017162265A1 (en) * | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| WO2017180770A1 (en) | 2016-04-13 | 2017-10-19 | Synthetic Genomics, Inc. | Recombinant arterivirus replicon systems and uses thereof |
| US12385034B2 (en) | 2016-06-24 | 2025-08-12 | Modernatx, Inc. | Methods and apparatus for filtration |
| JP7382230B2 (ja) | 2016-10-17 | 2023-11-16 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 組み換えウイルスレプリコン系及びその使用 |
| BR112019011661A2 (pt) * | 2016-12-05 | 2020-01-07 | Synthetic Genomics, Inc. | Composições e métodos para aumentar expressão de gene |
| TW201907937A (zh) | 2017-05-08 | 2019-03-01 | 美商葛利史東腫瘤科技公司 | 阿爾法病毒新抗原載體 |
| WO2019053012A1 (en) * | 2017-09-13 | 2019-03-21 | Biontech Rna Pharmaceuticals Gmbh | RNA REPLICON FOR THE REPROGRAMMING OF SOMATIC CELLS |
| US20200283497A1 (en) * | 2017-09-13 | 2020-09-10 | Biontech Cell & Gene Therapies Gmbh | Rna replicon for expressing at cell receptor or an artificial t cell receptor |
| US11167027B2 (en) | 2017-11-06 | 2021-11-09 | Intervet Inc. | Multivalent feline vaccine |
| CN118490817A (zh) | 2017-11-06 | 2024-08-16 | 英特维特国际股份有限公司 | 狂犬病毒疫苗 |
| WO2019110213A1 (en) | 2017-12-08 | 2019-06-13 | Intervet International B.V. | Feline calicivirus vaccine |
| WO2019086646A1 (en) | 2017-11-06 | 2019-05-09 | Intervet International B.V. | Feline leukemia virus vaccine |
| EP3706789A1 (en) | 2017-11-06 | 2020-09-16 | Intervet International B.V. | Feline calicivirus vaccine |
| BR112020011041A2 (pt) | 2017-12-04 | 2020-11-17 | Intervet International B.V. | vacina contra a doença de lyme canina |
| MX2020005584A (es) | 2017-12-04 | 2020-09-14 | Intervet Int Bv | Vacunacion con particulas de replicon y adyuvante oleoso. |
| AU2018383915B9 (en) | 2017-12-15 | 2023-06-01 | Intervet International B.V. | Multivalent feline vaccine |
| US12290556B2 (en) | 2017-12-18 | 2025-05-06 | Intervet Inc. | Swine influenza a virus vaccine |
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
| SG11202005792RA (en) | 2017-12-20 | 2020-07-29 | Vlp Therapeutics Llc | Alphavirus replicon particle |
| KR20200111729A (ko) | 2018-01-19 | 2020-09-29 | 얀센 파마슈티칼즈, 인코포레이티드 | 재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진 |
| US12331076B2 (en) | 2018-10-08 | 2025-06-17 | Janssen Pharmaceuticals, Inc. | Alphavirus-based replicons for administration of biotherapeutics |
| EP3897710A1 (en) | 2018-12-20 | 2021-10-27 | Intervet International B.V. | Prime-boost vaccination regimen |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| CA3171231A1 (en) * | 2020-03-09 | 2021-09-16 | Sean Michael Sullivan | Compositions and methods for inducing immune responses |
| EP4135847A4 (en) | 2020-04-17 | 2024-05-15 | VLP Therapeutics, Inc. | Coronavirus vaccine |
| WO2021221127A1 (en) | 2020-04-30 | 2021-11-04 | Vlp Therapeutics, Inc. | Cytokine immunotherapy |
| EP4149532A1 (en) | 2020-05-11 | 2023-03-22 | Intervet International B.V. | Feline severe acute respiratory syndrome coronavirus 2 vaccine |
| US20230277649A1 (en) | 2020-06-19 | 2023-09-07 | Intervet Inc. | Swine influenza a virus vaccine comprising two distinct rna replicon particles |
| WO2021255225A1 (en) | 2020-06-19 | 2021-12-23 | Intervet International B.V. | Swine influenza a virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding distinct neuraminidase antigens of the virus |
| EP4168041A1 (en) | 2020-06-19 | 2023-04-26 | Intervet International B.V. | Swine influenza a virus vaccine comprising a nucleic acid construct having a specific order of genes |
| CN115836082A (zh) | 2020-06-19 | 2023-03-21 | 英特维特国际股份有限公司 | 包含编码特定病毒谱系抗原的核酸构建体的甲型猪流感病毒疫苗 |
| EP4192496A4 (en) | 2020-08-06 | 2025-01-01 | Gritstone bio, Inc. | MULTIEPITOP VACCINE CASSETTES |
| EP4210740A1 (en) | 2020-09-07 | 2023-07-19 | Intervet International B.V. | Ha stem vaccine for ha antibody-positive targets |
| CA3198118A1 (en) | 2020-11-12 | 2022-05-19 | Martijn Alexander LANGEREIS | Recombinant vectors encoding chimeric coronavirus spike proteins and use thereof |
| CN118139640A (zh) | 2021-10-25 | 2024-06-04 | 英特维特国际股份有限公司 | 保护仔猪抵抗甲型猪流感病毒感染的疫苗 |
| EP4696782A1 (en) | 2024-08-14 | 2026-02-18 | Starvax One B.V. | Improved split rna replicons |
| WO2026037537A1 (en) | 2024-08-16 | 2026-02-19 | Intervet International B.V. | Canine influenza virus vaccine |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| NZ225583A (en) | 1987-08-06 | 1991-07-26 | Merck & Co Inc | Process for purifying hepatitis a virions (hav) |
| US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| US5185440A (en) | 1989-06-20 | 1993-02-09 | North Carolina State University | cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof |
| US6770283B1 (en) | 1990-12-13 | 2004-08-03 | Bioption Ab | DNA expression systems based on alphaviruses |
| SE9003978D0 (sv) | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
| AU6172194A (en) | 1993-02-08 | 1994-08-29 | Paravax, Inc. | Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens |
| US20020102273A1 (en) | 1995-08-08 | 2002-08-01 | Robert B. Grieve | Use of alphavirus expression vectors to produce parasite anitgens |
| RU2057377C1 (ru) | 1993-08-23 | 1996-03-27 | Уральский электрохимический комбинат | Способ переработки оружейного высокообогащенного урана и его сплавов в топливный материал для атомных реакторов |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| EP0711829A3 (en) | 1993-09-15 | 1997-07-09 | Viagene Inc | Recombinant alphavirus vector |
| SE9401091D0 (sv) | 1994-03-31 | 1994-03-31 | Bioption Ab | Alphavirus cDNA vectors |
| SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| FR2723849B1 (fr) | 1994-08-31 | 1997-04-11 | Biovector Therapeutics Sa | Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| US5639650A (en) | 1995-05-23 | 1997-06-17 | The University Of North Carolina At Chapel Hill | cDNA clone for South African Arbovirus No. 86 |
| US6197879B1 (en) * | 1995-10-31 | 2001-03-06 | Henkel Corporation | Methods of preparing inorganic pigment dispersions |
| US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| WO1997040165A1 (en) | 1996-04-23 | 1997-10-30 | The Wistar Institute Of Anatomy And Biology | Novel human cytomegalovirus dna constructs and uses therefor |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| CZ438398A3 (cs) | 1996-07-01 | 1999-03-17 | Rhone-Poulenc Rorer S. A. | Způsob přípravy rekombinantních adenovirů |
| JP2965908B2 (ja) | 1996-07-05 | 1999-10-18 | 株式会社精工技研 | 調温液体シール手段を備える光ディスク成形用金型装置 |
| US5827658A (en) | 1996-08-09 | 1998-10-27 | The United States Of America As Reprsented By The Department Of Health And Human Services | Isolation of amplified genes via cDNA subtractive hybridization |
| US5726022A (en) | 1996-11-18 | 1998-03-10 | Lifespan Biosciences, Inc. | Subtractive hybridization and capture methods and kits for differential isolation of nucleic acids including disease-associated sequences |
| WO1998022588A2 (en) | 1996-11-20 | 1998-05-28 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| FR2757169B1 (fr) | 1996-12-13 | 1999-03-05 | Inst Nat Sante Rech Med | Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin |
| US5811407A (en) | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
| US5958738A (en) | 1997-03-24 | 1999-09-28 | Roche Diagnostics Corporation | Procedure for subtractive hybridization and difference analysis |
| US6261570B1 (en) | 1997-05-20 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Army | Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants |
| GB9716611D0 (en) | 1997-08-07 | 1997-10-08 | Cantab Pharmaceuticals Res Ltd | Virus preparations and methods |
| AUPO856097A0 (en) | 1997-08-14 | 1997-09-04 | Commonwealth Scientific And Industrial Research Organisation | Vector |
| US6197502B1 (en) | 1997-11-17 | 2001-03-06 | Cytos Biotechnology Ag | Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property |
| GB9804632D0 (en) | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
| FI106618B (fi) | 1998-03-30 | 2001-03-15 | Sandvik Tamrock Oy | Sovitelma painenestekäyttöisen iskulaitteen, kuten esimerkiksi rikotuslaitteen yhteydessä |
| AU754320B2 (en) | 1998-04-08 | 2002-11-14 | University Of North Carolina At Chapel Hill, The | Methods and modified cells for the treatment of cancer |
| US6844188B1 (en) | 1998-04-08 | 2005-01-18 | University Of North Carolina At Chapel Hill | Methods and modified cells for the treatment of cancer |
| EP1080218A1 (en) | 1998-05-27 | 2001-03-07 | University of Florida | Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient |
| US7267823B2 (en) | 1998-06-29 | 2007-09-11 | United States Of America As Represented By The Secretary Of The Army | Ebola peptides and immunogenic compositions containing same |
| WO2000000616A2 (en) | 1998-06-29 | 2000-01-06 | U.S. Medical Research Institute Of Infectious Diseases | Marburg virus vaccines |
| US6770479B1 (en) | 1998-07-10 | 2004-08-03 | The United States Of America As Represented By The Secretary Of The Army | Anthrax vaccine |
| ATE382693T1 (de) | 1998-07-10 | 2008-01-15 | U S Army Medical Res Inst Of I | Impfstoffe gegen neurotoxine von clostridium botulinum |
| DE69940157D1 (en) | 1998-07-10 | 2009-02-05 | U S Medical Res Inst Of Infect | Anthrax-impfstoff |
| AU6289699A (en) | 1998-10-05 | 2000-04-26 | Genzyme Corporation | Genes differentially expressed in cancer cells to design cancer vaccines |
| US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| WO2000039318A1 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
| US6329201B1 (en) | 1998-12-31 | 2001-12-11 | Chiron Corporation | Compositions and methods for packaging of alphavirus vectors |
| EP1980617A1 (en) | 1998-12-31 | 2008-10-15 | Novartis Vaccines and Diagnostics, Inc. | Improved expression of HIV polypeptides and production of virus-like particles |
| DK1175497T3 (da) | 1999-04-14 | 2010-05-31 | Novartis Vaccines & Diagnostic | Præparater og fremgangsmåder til generering af et immunrespons ved udnyttelse af alfavirusbaserede vektorsystemer |
| AU782645B2 (en) | 1999-08-31 | 2005-08-18 | University Of North Carolina At Chapel Hill, The | Antibody dependent enhancement (ADE) of alphavirus infection |
| EP1222299A1 (en) * | 1999-10-01 | 2002-07-17 | Genovo, Incorporated | Production of recombinant aav using adenovirus comprising aav rep/cap genes |
| US7115391B1 (en) | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
| AU2001275191A1 (en) | 2000-05-31 | 2001-12-11 | Chiron Corporation | Method for the purification of alphavirus replicon particles |
| WO2002003917A2 (en) | 2000-07-07 | 2002-01-17 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified hiv genes for use as vaccines |
| US6783939B2 (en) | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
| DE60103902T2 (de) | 2000-07-28 | 2005-06-30 | Visteon Global Technologies, Inc., Dearborn | Ansaugsystem für brennkraftmaschine |
| CN1250731C (zh) | 2000-08-29 | 2006-04-12 | 惠氏控股公司 | 正链rna病毒复制子颗粒的包装 |
| US6982087B2 (en) | 2000-09-07 | 2006-01-03 | The University Of North Carolina At Chapel Hill | Vectors derived from South African Arbovirus No. 86 |
| DE10049587A1 (de) | 2000-10-06 | 2002-05-02 | Icon Genetics Ag | Vektorsystem für Pflanzen |
| DE10061150A1 (de) | 2000-12-08 | 2002-06-13 | Icon Genetics Ag | Verfahren und Vektoren zur Erzeugung von transgenen Pflanzen |
| US6800289B2 (en) | 2000-12-21 | 2004-10-05 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Strain of the western equine encephalitis virus |
| AU2002305914A1 (en) | 2001-01-12 | 2002-10-21 | Chiron Corporation | Nucleic acid mucosal immunization |
| DE10121283B4 (de) | 2001-04-30 | 2011-08-11 | Icon Genetics GmbH, 80333 | Verfahren und Vektoren zur Amplifikation oder Expression von gewünschten Nucleinsäuresequenzen in Pflanzen |
| US20030232324A1 (en) | 2001-05-31 | 2003-12-18 | Chiron Corporation | Chimeric alphavirus replicon particles |
| AU2002303330B2 (en) | 2001-05-31 | 2008-07-24 | Novartis Vaccines And Diagnostics, Inc. | Chimeric alphavirus replicon particles |
| DE10143237A1 (de) | 2001-09-04 | 2003-03-20 | Icon Genetics Ag | Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente) |
| DE10143238A1 (de) | 2001-09-04 | 2003-03-20 | Icon Genetics Ag | Identifizierung eukaryotischer interner Ribosomen-Eingangsstellen (IRES)-Elemente |
| US7045335B2 (en) | 2001-09-06 | 2006-05-16 | Alphavax, Inc. | Alphavirus replicon vector systems |
| WO2003083065A2 (en) | 2002-03-25 | 2003-10-09 | University Of North Carolina At Chapel Hill | Improved methods for achieving expression from alphavirus vectors |
| JP3857195B2 (ja) | 2002-07-09 | 2006-12-13 | 株式会社東芝 | 距離継電装置 |
| US20050031592A1 (en) | 2002-11-13 | 2005-02-10 | Doolan Denise L. | Methods and compositions for inducing immune responses and protective immunity by priming with alpha virus replicon vaccines |
| EP1585812B1 (en) | 2002-12-13 | 2017-01-18 | Alphavax, Inc. | Multi-antigenic alphavirus replicon particles and methods |
| JP5079981B2 (ja) | 2002-12-13 | 2012-11-21 | アルファバックス，インコーポレイティド | アルファウイルス粒子及び調製方法 |
| KR101518309B1 (ko) | 2003-03-20 | 2015-05-08 | 알파벡스, 인크. | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 |
| US20060099587A1 (en) | 2003-06-20 | 2006-05-11 | Johnston Robert E | Alphavirus vectors having attentuated virion structural proteins |
| EP1651666B1 (en) | 2003-07-11 | 2009-05-27 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
| US20050208020A1 (en) | 2003-11-12 | 2005-09-22 | Doolan Denise L | Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines |
| US7078087B2 (en) * | 2003-12-31 | 2006-07-18 | Kimberly-Clark Worldwide, Inc. | Wipes with an edge treatment along a leading edge portion |
| ES2321212T3 (es) | 2004-05-18 | 2009-06-03 | Alphavax, Inc. | Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion. |
| US7862829B2 (en) | 2004-07-09 | 2011-01-04 | University Of North Carolina At Chapel Hill | Viral adjuvants |
| WO2007046839A2 (en) | 2005-02-15 | 2007-04-26 | University Of North Carolina At Chapel Hill | New live virus vaccines |
| ES2517869T3 (es) | 2006-09-12 | 2014-11-04 | Alphavax, Inc. | Partículas de replicones de alfavirus emparejadas con antígenos proteicos como adyuvantes inmunológicos |
| DK2183368T3 (en) | 2007-06-21 | 2016-09-05 | Alphavax Inc | PROMOTER-FREE CASES FOR EXPRESSION OF ALPHAVIRUS STRUCTURE PROTEINS |
| CN102083986B (zh) * | 2008-01-24 | 2014-06-18 | 德克萨斯大学系统董事会 | 不能在蚊子中复制的减毒重组甲病毒及其用途 |
-
2008
- 2008-06-20 DK DK08825920.5T patent/DK2183368T3/en active
- 2008-06-20 US US12/665,497 patent/US8460913B2/en active Active
- 2008-06-20 ES ES15173487.8T patent/ES2670813T3/es active Active
- 2008-06-20 WO PCT/US2008/007701 patent/WO2008156829A2/en not_active Ceased
- 2008-06-20 CA CA2689588A patent/CA2689588C/en active Active
- 2008-06-20 JP JP2010513254A patent/JP5602624B2/ja active Active
- 2008-06-20 DK DK15173487.8T patent/DK2947149T3/en active
- 2008-06-20 CN CN2008801036605A patent/CN101802199B/zh active Active
- 2008-06-20 US US12/143,320 patent/US7850977B2/en active Active
- 2008-06-20 ES ES08825920.5T patent/ES2588906T3/es active Active
- 2008-06-20 EP EP15173487.8A patent/EP2947149B1/en active Active
- 2008-06-20 NZ NZ582495A patent/NZ582495A/en unknown
- 2008-06-20 EP EP08825920.5A patent/EP2183368B1/en active Active
- 2008-06-20 AU AU2008266807A patent/AU2008266807B2/en active Active
- 2008-06-20 PL PL08825920.5T patent/PL2183368T3/pl unknown
- 2008-06-20 PL PL15173487T patent/PL2947149T3/pl unknown
-
2009
- 2009-12-14 IL IL202720A patent/IL202720A/en active IP Right Grant
- 2009-12-18 ZA ZA200909080A patent/ZA200909080B/xx unknown
-
2014
- 2014-08-20 JP JP2014167257A patent/JP5995926B2/ja active Active
-
2016
- 2016-08-23 JP JP2016162382A patent/JP2016198114A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008266807A1 (en) | 2008-12-24 |
| ZA200909080B (en) | 2010-09-29 |
| EP2183368B1 (en) | 2016-08-10 |
| PL2947149T3 (pl) | 2018-09-28 |
| AU2008266807B2 (en) | 2012-08-16 |
| US20090075384A1 (en) | 2009-03-19 |
| NZ582495A (en) | 2012-05-25 |
| ES2588906T3 (es) | 2016-11-07 |
| JP5602624B2 (ja) | 2014-10-08 |
| WO2008156829A2 (en) | 2008-12-24 |
| DK2183368T3 (en) | 2016-09-05 |
| DK2947149T3 (en) | 2018-06-06 |
| CN101802199B (zh) | 2012-08-22 |
| HK1217216A1 (en) | 2016-12-30 |
| JP2016198114A (ja) | 2016-12-01 |
| IL202720A (en) | 2013-10-31 |
| JP5995926B2 (ja) | 2016-09-21 |
| US8460913B2 (en) | 2013-06-11 |
| IL202720A0 (en) | 2011-08-01 |
| WO2008156829A3 (en) | 2009-03-12 |
| EP2947149A1 (en) | 2015-11-25 |
| JP2010530245A (ja) | 2010-09-09 |
| EP2183368A4 (en) | 2011-04-13 |
| JP2014230544A (ja) | 2014-12-11 |
| CN101802199A (zh) | 2010-08-11 |
| PL2183368T3 (pl) | 2016-12-30 |
| ES2670813T3 (es) | 2018-06-01 |
| CA2689588A1 (en) | 2008-12-24 |
| EP2947149B1 (en) | 2018-02-28 |
| US7850977B2 (en) | 2010-12-14 |
| EP2183368A2 (en) | 2010-05-12 |
| US20100183665A1 (en) | 2010-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2183368B1 (en) | Promoterless cassettes for expression of alphavirus structural proteins | |
| US10570416B2 (en) | TC-83-derived alphavirus vectors, particles and methods | |
| KR101518309B1 (ko) | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 | |
| EP1585812B1 (en) | Multi-antigenic alphavirus replicon particles and methods | |
| HK1217216B (en) | Alphavirus replicon particles for use in vaccination | |
| HK1084692B (en) | Improved alphavirus replicons and helper constructs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130610 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD Year of fee payment: 17 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250430 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250430 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD Year of fee payment: 18 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260505 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260505 |